Effect of sickle cell diseases on height and weight

Pakistan Journal of Medical Sciences

Volumn 27, Issue 2, 2011, Pages 361-364

  Helvaci, Mehmet Rami ^a   Kaya, Hasan ^a  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

Author keywords

Height; Heredity; Sickle cell diseases

Indexed keywords

ALANINE AMINOTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; SICKLE CELL ANEMIA; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 79956145650     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Rona RJ, Chinn S. Genetic and environmental influences on growth. J Med Screen. 1995;2:133-139.
2. Preece MA. The genetic contribution to stature. Horm Res. 1996;45:56-58.
3. Habicht JP, Martorell R, Yarbrough C, Malina RM, Klein RE. Height and weight standards for preschool children. How relevant are ethnic differences in growth potential? Lancet. 1974;1:611-614.
4. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639-1644.
5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;17:106:3143-3421.
6. Herrick JB. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch Intern Med. 1910;6:517-521.
7. Parfrey NA, Moore W, Hutchins GM. Is pain crisis a cause of death in sickle cell disease? Am J Clin Pathol. 1985;84:209-212.
8. Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;342:83-89.
9. Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr. 1992;120:360-366.
10. Cole TB, Sprinkle RH, Smith SJ, Buchanan GR. Intravenous narcotic therapy for children with severe sickle cell pain crisis. Am J Dis Child. 1986;140:1255-1259.
11. Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics. 1989;84:500-508.
12. Haupt HM, Moore GW, Bauer TW, Hutchins GM. The lung in sickle cell disease. Chest. 1982;81:332-337.
13. Shapiro MP, Hayes JA. Fat embolism in sickle cell disease. Report of a case with brief review of the literature. Arch Intern Med. 1984;144:181-182.
14. Hutchinson RM, Merrick MV, White JM. Fat embolism in sickle cell disease. J Clin Pathol. 1973;26:620-622.
15. Al-Saqladi AW, Cipolotti R, Fijnvandraat K, Brabin BJ. Growth and nutritional status of children with homozygous sickle cell disease. Ann Trop Paediatr. 2008;28:165-189.
16. Zemel BS, Kawchak DA, Ohene-Frempong K, Schall JI, Stallings VA. Effects of delayed pubertal development, nutritional status, and disease severity on longitudinal patterns of growth failure in children with sickle cell disease. Pediatr Res. 2007;61:607-613.
17. Helvaci MR, Kaya H, Yalcin A, Kuvandik G. Prevalence of white coat hypertension in underweight and overweight subjects. Int Heart J. 2007;48:605-613.
18. Helvaci MR, Kaya H, Duru M, Yalcin A. What is the relationship between white coat hypertension and dyslipidemia? Int Heart J. 2008;49:87-93.
19. Helvaci MR, Kaya H, Sevinc A, Camci C. Body weight and white coat hypertension. Pak J Med Sci. 2009;25:6:916-921.
20. Khoury MJ. Genetic epidemiology and the future of disease prevention and public health. Epidemiol Rev. 1997;19:175-180.
21. Xu H, Xiong DH, Xu FH, Zhang YY, Lei SF, Deng HW. Association between VDR Apal polymorphism and hip bone mineral density can be modified by body mass index: A study on postmenopausal Chinese women. Acta Biochim Biophys Sin. 2005;37:61-67.
22. Riley DG, Coleman SW, Chase CC Jr, Oslon TA, Hammond AC. Genetic parameters of body weight, hip height, and the ratio of weight to hip height from random regression analyses of Brahman feedlot cattle. J Anim Sci. 2007;85:42-52.
23. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normalweight and obese humans. N Engl J Med. 1996;334:292-295.
24. Reseland JE, Syversen U, Bakke I, Qvigstad G, Eide LG, Hjertner O, et al. Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J Bone Miner Res. 2001;16:1426-1433.
25. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000;100:197-207.
26. Livshits G, Pantsulaia I, Trofimov S, Kobyliansky E. Genetic variation of circulating leptin is involved in genetic variation of hand bone size and geometry. Osteoporos Int. 2003;14:476-483.
27. Livshits G, Peter I, Vainder M, Hauspie R. Genetic analysis of growth curve parameters of body weight, height and head circumference. Ann Hum Biol 2000;27:299-312.